FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897747424> ?p ?o ?g. }

• W2897747424 endingPage "e14" @default.
• W2897747424 startingPage "16" @default.
• W2897747424 abstract "Abstract Lessons Learned Vandetanib at a dose of 300 mg orally every day plus bortezomib 1.3 mg/m2 intravenously on days 1, 4, 8, and 11 could be administered safely. Assessing outcomes in 17 patients with medullary thyroid cancer, investigators considered the combination to be more difficult to administer than single-agent vandetanib and that achieving better outcomes was unlikely. Consequently, a planned phase II study was terminated early. Background The proto-oncogene RET (REarranged during Transfection) has a critical role in the pathogenesis of medullary thyroid cancer (MTC). Vandetanib (V), a multitargeted tyrosine kinase inhibitor approved for the treatment of MTC, is thought to inhibit RET in MTC. Supported by preclinical studies demonstrating that bortezomib (B) administration lowered RET mRNA and protein levels, we conducted a phase I study in advanced solid tumors of vandetanib in combination with bortezomib. The goal was to establish an RP2D (recommended phase II dose) for the combination of vandetanib plus bortezomib, a regimen envisioned as a dual strategy for targeting RET in MTC. Methods Patients with advanced solid tumors were treated with escalating doses of bortezomib or vandetanib to assess the safety and tolerability of daily oral vandetanib and intravenous (IV) bortezomib administered on days 1, 4, 8, and 11 of a 28-day cycle. Intrapatient dose escalation was allowed. Results Twenty-two patients were enrolled and received escalating mg/m2 bortezomib and mg vandetanib (number of patients) at initial doses of 1 and 100 (3), 1.3 and 100 (6), 1.3 and 200 (6), and 1.3 and 300 (7), respectively. Patients received a median of four cycles of bortezomib/vandetanib (range: 1–10), with 13 patients escalating to 1.3/200 and 10 to 1.3/300. G3 toxicities occurring in more than one patient included hypertension (24%), fatigue (19%), thrombocytopenia (10%), diarrhea (10%), and arthralgia (10%). There were no drug-related G4/5 toxicities. There was one dose-limiting toxicity, G3 thrombocytopenia, at bortezomib/vandetanib doses of 1.3/200 in cycle 2 that resolved without intervention. Four patients with a diagnosis of MTC (27%) had a partial response (PR). Conclusion The MTD of the combination was established as bortezomib, 1.3 mg/m2 IV days 1, 4, 8, and 11 with vandetanib 300 mg p.o. daily. RECIST responses were observed in patients with a diagnosis of MTC." @default.
• W2897747424 created "2018-10-26" @default.
• W2897747424 creator A5006092876 @default.
• W2897747424 creator A5008898573 @default.
• W2897747424 creator A5019539470 @default.
• W2897747424 creator A5021270693 @default.
• W2897747424 creator A5033887044 @default.
• W2897747424 creator A5044285326 @default.
• W2897747424 creator A5055085301 @default.
• W2897747424 date "2018-10-08" @default.
• W2897747424 modified "2023-10-16" @default.
• W2897747424 title "Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer" @default.
• W2897747424 cites W1488386819 @default.
• W2897747424 cites W1534448933 @default.
• W2897747424 cites W1966406203 @default.
• W2897747424 cites W1971229911 @default.
• W2897747424 cites W1979959940 @default.
• W2897747424 cites W1998011705 @default.
• W2897747424 cites W2013522785 @default.
• W2897747424 cites W2033043245 @default.
• W2897747424 cites W2042148986 @default.
• W2897747424 cites W2044683004 @default.
• W2897747424 cites W2044761914 @default.
• W2897747424 cites W2046385362 @default.
• W2897747424 cites W2072846453 @default.
• W2897747424 cites W2078766933 @default.
• W2897747424 cites W2078851958 @default.
• W2897747424 cites W2101151768 @default.
• W2897747424 cites W2106695112 @default.
• W2897747424 cites W2109833554 @default.
• W2897747424 cites W2112129582 @default.
• W2897747424 cites W2112475888 @default.
• W2897747424 cites W2115068822 @default.
• W2897747424 cites W2119501407 @default.
• W2897747424 cites W2122956665 @default.
• W2897747424 cites W2125916043 @default.
• W2897747424 cites W2126932086 @default.
• W2897747424 cites W2129276274 @default.
• W2897747424 cites W2133762340 @default.
• W2897747424 cites W2136146667 @default.
• W2897747424 cites W2137709853 @default.
• W2897747424 cites W2145982482 @default.
• W2897747424 cites W2146718153 @default.
• W2897747424 cites W2148214379 @default.
• W2897747424 cites W2159075642 @default.
• W2897747424 cites W2160863198 @default.
• W2897747424 cites W2162933215 @default.
• W2897747424 cites W2401565151 @default.
• W2897747424 cites W3198152983 @default.
• W2897747424 cites W4295768330 @default.
• W2897747424 doi "https://doi.org/10.1634/theoncologist.2018-0452" @default.
• W2897747424 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324636" @default.
• W2897747424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30297385" @default.
• W2897747424 hasPublicationYear "2018" @default.
• W2897747424 type Work @default.
• W2897747424 sameAs 2897747424 @default.
• W2897747424 citedByCount "12" @default.
• W2897747424 countsByYear W28977474242019 @default.
• W2897747424 countsByYear W28977474242020 @default.
• W2897747424 countsByYear W28977474242021 @default.
• W2897747424 countsByYear W28977474242022 @default.
• W2897747424 countsByYear W28977474242023 @default.
• W2897747424 crossrefType "journal-article" @default.
• W2897747424 hasAuthorship W2897747424A5006092876 @default.
• W2897747424 hasAuthorship W2897747424A5008898573 @default.
• W2897747424 hasAuthorship W2897747424A5019539470 @default.
• W2897747424 hasAuthorship W2897747424A5021270693 @default.
• W2897747424 hasAuthorship W2897747424A5033887044 @default.
• W2897747424 hasAuthorship W2897747424A5044285326 @default.
• W2897747424 hasAuthorship W2897747424A5055085301 @default.
• W2897747424 hasBestOaLocation W28977474241 @default.
• W2897747424 hasConcept C121608353 @default.
• W2897747424 hasConcept C126322002 @default.
• W2897747424 hasConcept C143998085 @default.
• W2897747424 hasConcept C170493617 @default.
• W2897747424 hasConcept C2776364478 @default.
• W2897747424 hasConcept C2777478702 @default.
• W2897747424 hasConcept C2778820342 @default.
• W2897747424 hasConcept C2779761222 @default.
• W2897747424 hasConcept C2780120053 @default.
• W2897747424 hasConcept C2780333294 @default.
• W2897747424 hasConcept C31760486 @default.
• W2897747424 hasConcept C42362537 @default.
• W2897747424 hasConcept C535046627 @default.
• W2897747424 hasConcept C71924100 @default.
• W2897747424 hasConcept C98274493 @default.
• W2897747424 hasConceptScore W2897747424C121608353 @default.
• W2897747424 hasConceptScore W2897747424C126322002 @default.
• W2897747424 hasConceptScore W2897747424C143998085 @default.
• W2897747424 hasConceptScore W2897747424C170493617 @default.
• W2897747424 hasConceptScore W2897747424C2776364478 @default.
• W2897747424 hasConceptScore W2897747424C2777478702 @default.
• W2897747424 hasConceptScore W2897747424C2778820342 @default.
• W2897747424 hasConceptScore W2897747424C2779761222 @default.
• W2897747424 hasConceptScore W2897747424C2780120053 @default.
• W2897747424 hasConceptScore W2897747424C2780333294 @default.
• W2897747424 hasConceptScore W2897747424C31760486 @default.
• W2897747424 hasConceptScore W2897747424C42362537 @default.

• next